Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
ABUSE-DETERRENT MARKET - What’s in the Pipeline? Abuse-Deterrent Products November 18, 2014
Tugrul Kararli, PhD, MBA, Kurt Sedo, and Josef Bossart, PhD, decided it would be interesting to interrogate the PharmaCircle database and see what successes have been achieved with respect to abuse-deterrent formulations in terms of approved and pipeline products.
DNA VACCINES MARKET - DNA Vaccines: Strategic Markets & Emerging Technologies November 17, 2014
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
Acorda Therapeutics to Acquire Civitas Therapeutics September 30, 2014
Acorda Therapeutics, Inc. recently announced it entered into an agreement to acquire Civitas Therapeutics, a privately held biopharmaceutical company, for...Implementing Innovations in Injectable Drug Delivery With the User & Pharmaceutical Manufacturer in Mind September 23, 2014
By: John A. Merhige, Chief Commercial Officer, and Dan Thayer, Technology Director, Credence MedSystems, Inc. The Current Climate Change is...SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
SPECIAL FEATURE - Patients & Physicians Desire Transdermal, Topical & Subcutaneous Delivery July 9, 2014
Contributor Cindy H. Dubin recently interviewed several topical, transdermal, and subcutaneous product manufacturers to find out how they are working with patients and physicians to develop delivery systems that meet their needs for comfort, compliance, and more effective delivery.
INJECTABLE MICROEMULSIONS - Prolonged-Release Injectable Microemulsions: Opportunities for Pain Treatment June 4, 2014
Rajesh Dubey, PhD, and Luigi G. Martini, FRPharmS, MBA, indicate available technologies do not support development of certain formulations to treat pain; however, microemulsions with their unique features, can provide a viable alternative to develop such formulations.
Capsugel & Bend Research Announce New Commercial-Scale Spray-Dried Dispersion Capacity June 3, 2014
Bend Research, a division of Capsugel Dosage Form Solutions (DFS), recently announced it has installed its first commercial-scale spray-dryer in...EXECUTIVE INTERVIEW - 4P Therapeutics: Developing New & Innovative Transdermal Products June 3, 2014
Drug Development Executive: Steven Damon, Founder of 4P Therapeutics, discusses his vision for the company and how 4P intends to create new and innovative transdermal products that meet the needs of patients, physicians, and payers.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing - Product Differentiation Is Critical May 8, 2014
Contributor Cindy H. Dubin speaks with several of these suppliers and manufacturers about the importance of customization and differentiation as the key to pharma companies staying competitive in the prefilled syringe space.
Prosonix & Mylan Enter Global Licensing Agreement April 22, 2014
Prosonix recently announced it has entered into a global licensing agreement with Mylan Inc. for its leading inhaled respiratory products,...Oval Medical Receives Funding to Progress Container for Autoinjector Techgnology April 22, 2014
Oval Medical Technologies Limited recently announced it has received a Smart funding award from the UK’s innovation agency, the Technology...Ensysce Biosciences Receives Patent for siRNA Delivery March 21, 2014
Ensysce Biosciences Inc. recently announced the US Patent Office has issued a Notice of Allowance for US Patent Application No....ADVANCED DELIVERY DEVICES - New Drug Delivery & Stabilization Platforms Gaining Global Interest March 5, 2014
Sam de Costa, PhD, believes the launch of two stabilization and drug delivery platforms that have the potential to revolutionize the delivery of vaccines, therapeutics, and diagnostics, while significantly cutting costs, has attracted sharp interest from pharmaceutical and biotech companies around the world.
SPECIAL FEATURE- Analytical Testing of Biologics & Biosimilars March 5, 2014
Contributor Cindy H. Dubin talks with some of the leading experts in the industry about the importance of outsourcing analytical testing in the biologic/biosimilar space, the associated challenges, and how to ensure products get to market safely and quickly.
Tekmira Presents Recent Advances in mRNA Delivery February 28, 2014
Tekmira Pharmaceuticals Corporation recently announced that recent advances in the enablement of messenger RNA (mRNA) using Tekmira's lipid nanoparticle (LNP)...NantBioScience Announces Strategic Collaboration With Celgene January 21, 2014
NantBioScience recently announced a strategic collaboration with Celgene to advance bold research programs to benefit cancer patients in need of...EXECUTIVE INTERVIEW - Aptar Pharma: From Self-Injection to Auto-Injection November 20, 2013
Pierre Carlotti, Vice-President of Marketing and Communication for Aptar Pharma Prescription Division, talks about the market for auto-injectors and some relevant market trends, and explains how his company went about designing and developing a novel auto-injector.
BIOAVAILABILITY ENHANCEMENT - Navigating a Broad Spectrum of Solubilization Technologies: Part III of III November 19, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., concludes his multiple-part series discussing today’s most challenging issues in solubility.
EXECUTIVE INTERVIEW - Catalent Applied Drug Delivery Institute: Helping to Get Better Drugs to Waiting Patients, Encouraging the Adoption of Advanced Delivery Technologies November 19, 2013
Drug Development Executive: Kurt Nielsen, PhD, CTO & SVP, Innovation & Growth, and Founding Institute Board Member, discusses the Institute, its goals, structure, and activities.
